Tryptophanase engineered into the vector VNP20009, which was previously been studied in preclinical and human clinical trials where it was shown to target tumors, warrants further studies in murine models of triple-negative breast cancer. This evidence concerns the gene TDO2 and triple-negative breast carcinoma.